AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

A DeepMind spinoff, Isomorphic Labs, is moving AI-designed drugs into human trials. The company's president, Max Jaderberg, highlighted an 'exciting pipeline of new medicines' at WIRED Health in London.